NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.34 -0.59 (-0.72%) GOLD FUTURES
2,300.00 -2.90 (-0.13%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,490.15 -2,262.02 (-4.46%)
Novartis AG (NVSEF)
| Previous close | 96.00 |
| Open | 97.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 97.00 - 97.00 |
| 52-week range | 90.12 - 109.00 |
| Volume | |
| Avg. volume | 43,769 |
| Market cap | 200.455B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.05 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (3.92%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- Zacks
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- Zacks
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Reuters
Morphosys says takeover by Novartis on course after report of drug safety concern
BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday. Morphosys' statement came after a report by specialist website STAT News, citing two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.
